Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triamcinolone vs Verapamil for Keloids
NCT06897969Phase 4
Key facts
- Status
- Not yet recruiting
- Start
- Apr 2025
- Primary completion
- Sep 2025
- Countries
- 1
- Sponsor
- Nishtar Medical University
- Modality
- Orthosteric Ligands
- Conditions
- keloid
01
Overview
Phase 4, randomised, single-blind trial of triamcinolone acetonide in keloid (2 arms), sponsored by Nishtar Medical University. Primary endpoint: Change in Vancouver Scar Score at 16 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Design
2 arms- Study design
- RandomizedSingle-blind
Verapamil Treatment
Intralesional Verapamil 2.5mg monthly
Triamcinolone Treatment
Intralesional Triamcinolone Acetonide 40mg monthly
03
Who it enrols
Patients with keloids 1-5 cm in size, duration < 5 years, and VSS >= 5. Excludes pregnant/lactating women, family history of keloids, acromegaly, and congestive cardiac diseases.
04
Endpoints
Primary
Change in Vancouver Scar Score
Beyond the preview
Go deeper on NCT06897969.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06897969.